DUBLIN, Calif., Dec. 2 /PRNewswire-FirstCall/ -- SuperGen, Inc. , a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the company's plans to present three posters at the 50th American Society of Hematology (ASH) Annual Meeting & Exposition on December 7 and 8, 2008.
SuperGen's presentations will review clinical and non-clinical advances in the following compounds: SGI-1776, SGI-1252, and SGI-110. All presentations will occur as poster presentations.
About SuperGen
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.
CONTACT: Timothy L. Enns, SVP, Corporate Communications & Business
Development of SuperGen, Inc., +1-925-560-2810, tenns@supergen.com; or
Media, Michael Beckerich for SuperGen, Inc., +1-212-677-7632,
mbeckerich@dorland.com
Web site: http://www.supergen.com/
